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INTRODUCTION:Malaria remains adevastat-
ing disease, affecting 216 million people annu-
ally, with 445,000 deaths occurring primarily in
children under 5 years old.Malaria treatment
relies primarily ondrugs that target the disease-
causingasexualbloodstages (ABS)ofPlasmodium
parasites, the organisms responsible for human
malaria. Whereas travelers may rely on short-
termdaily chemoprotective drugs, those living in
endemic regions require long-termmalaria pro-
tection such as insecticide-treated nets (ITNs)
and vector control. However, ITNs do not fully
shield individuals from malaria, may lose po-
tency with time, and can be bulky and difficult
to use. Another concern is that mosquitos may
become resistant to the active insecticides that
are used in ITNs and vector control.
RATIONALE: As the possibility of malaria
elimination becomesmore tangible, the ideal
antimalarial medicine profile should include
chemoprotection. Chemoprotectivemedicines
typically work against the exoerythrocytic par-
asite forms that invade and develop in the liver
andare responsible for the earliest asymptomatic
stage of the infection. Suchmedicines could be
formulated to provide long-acting prophylaxis,
safeguarding individuals that are living near or
traveling to areas that have been cleared of
parasites. Long-acting che-
moprotection in endemic
regions could also greatly
reduce circulatingparasite
numbersandpotentially re-
place a vaccine in an elim-
inationcampaign.Although
millions of compounds have been screened for
activity against parasiteABS, and somehavebeen
subsequently tested for potential prophylactic ac-
tivity, large-scale searches thatbeginwithprophy-
lactic activity havenot beenperformedbecauseof
the complexity of the assay: This assay requires
theproductionof infected laboratory-rearedmos-
quitoes and hand-dissection of the sporozoite-
infected salivary glands frommosquito thoraxes.
RESULTS: Todiscover leads fornext-generation
chemoprotective antimalarial drugs, we used
luciferase-expressingPlasmodium spp. parasites,
dissected from more than a million mosquitoes
over a 2-year period, to test more than 500,000
compounds for their ability to inhibit liver-stage
developmentofmalaria (681 compoundsshowed
ahalf-maximal inhibitoryconcentrationof<1mM).
Cluster analysis identified potent andpreviously
unreported scaffold families, as well as other
series previously associatedwith chemoprophy-
laxis. These leads were further tested through
multiple phenotypic assays that predict stage-
specific and multispecies antimalarial activity.
This work revealed compound classes that are
likely to provide symptomatic relief fromblood-
stage parasitemia in addition to providing pro-
tection.Target identificationbyuseof functional
assays, in vitro evolution, or metabolic profiling
revealed 58 mitochondrial inhibitors but also
many chemotypes possibly with previously un-
knownmechanisms of action, somewhichmay
disrupt the host pathogen signaling.
CONCLUSION: Our data substantially expands
the set of compounds with demonstrated activ-
ity against two known targets of chemoprotective
drugs, cytochrome bc1 and dihydroorotate dehy-
drogenase. These present a rich collection of chem-
ical diversity that may be exploited by members
of the community seeking to accelerate malaria
eliminationwith chemoprotection and chemopro-
phylaxis through open-source drug discovery.▪
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A Plasmodium vivax liver-stage schizont on a lawn of hepatocytes. The parasite schizont
has been stained with antibodies to parasite HSP70 (red) and UIS4 (yellow). Cell (parasite
and hepatoma) nuclei are shown in blue. This study identifies compounds that can prevent
the development of these liver-stage parasites and may function as chemoprotective drugs
for malaria.
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RESEARCH ARTICLE
◥
ANTIMALARIALS
Open-source discovery of chemical
leads for next-generation
chemoprotective antimalarials
Yevgeniya Antonova-Koch1, Stephan Meister1*, Matthew Abraham1, Madeline R. Luth1,
Sabine Ottilie1, Amanda K. Lukens2,3, Tomoyo Sakata-Kato3, Manu Vanaerschot4,
Edward Owen5, Juan Carlos Jado1, Steven P. Maher6,7, Jaeson Calla1,
David Plouffe8, Yang Zhong8, Kaisheng Chen8, Victor Chaumeau9,10,
Amy J. Conway6,7, Case W. McNamara8†, Maureen Ibanez8, Kerstin Gagaring8†,
Fernando Neria Serrano11, Korina Eribez1, Cullin McLean Taggard1, Andrea L. Cheung1,
Christie Lincoln1, Biniam Ambachew1, Melanie Rouillier12, Dionicio Siegel13,
François Nosten9,10, Dennis E. Kyle6,7, Francisco-Javier Gamo12, Yingyao Zhou8,
Manuel Llinás5,14, David A. Fidock4, Dyann F. Wirth2,3, Jeremy Burrows12,
Brice Campo12, Elizabeth A. Winzeler1,13‡
To discover leads for next-generation chemoprotective antimalarial drugs, we testedmore than
500,000 compounds for their ability to inhibit liver-stage development of luciferase-expressing
Plasmodium spp. parasites (681 compounds showed a half-maximal inhibitory concentration
of less than 1micromolar). Cluster analysis identified potent and previously unreported scaffold
families as well as other series previously associated with chemoprophylaxis. Further testing
through multiple phenotypic assays that predict stage-specific and multispecies antimalarial
activity distinguished compound classes that are likely to provide symptomatic relief by
reducing asexual blood-stage parasitemia from those which are likely to only prevent malaria.
Target identification by using functional assays, in vitro evolution, or metabolic profiling
revealed 58 mitochondrial inhibitors but also many chemotypes possibly with previously
unidentified mechanisms of action.
M
alaria remains a devastating disease, with
216 million annual cases and 445,000
deaths, primarily in children under 5 years
old. Malaria treatment relies primarily
on drugs that target the disease-causing
asexual blood stages (ABS) of the parasite
Plasmodium falciparum. These drugs include
the 4-aminoquinolines piperaquine and amodi-
aquine, the antifolates pymimethamine and
sulfadoxine, and the endoperoxides artemisinin
and its derivatives artesunate, artemether, and
dihydroartemisinin (1). Artemisinin-based com-
bination therapies (ACTs, such as artemether-
lumefantrine) are being used worldwide as
first-line treatments (1).
Although estimated malaria mortality rates
have decreased by 47%worldwide since 2000 (1),
in Southeast Asia resistance has emerged to the
artemisinins, and ACT treatment failures are
rising (2). In anticipation of eventual widespread
ACT failure, there has been a focused and co-
ordinated effort to place new antimalarial can-
didates into the drug development pipeline (www.
mmv.org/research-development/rd-portfolio) (3).
However, in vitro resistance can be generated
for most of these new classes in ABS parasites
(4), suggesting that the antimalarial pipeline
will require continuous replenishment.
An alternative approach is to create drugs that
prevent malaria by inhibiting parasites during
their initial stage of development in the liver be-
fore their initiation of symptomatic blood-stage
infection. Using chemotherapy for prophylaxis is
a well-established tool to prevent malaria caused
by different Plasmodium spp. To prevent malaria,
travelersmay take oral atovaquone plus proguanil,
doxycycline, or mefloquine. In endemic regions
of seasonal malaria in West Africa, children are
given SPAQ [sulphadoxine-pyrimethamine (SP)
plus amodiaquine] as seasonal malaria chemo-
prevention, and pregnant women, who are the
most vulnerable group, may also take SP for
intermittent preventative therapy (5).
Drugs that selectively affect the developing
liver stages of P. falciparum and the relapsing
species, Plasmodium vivax, have the potential
to engage new protein targets not present nor
required in parasite blood stages. Such drugs
could overcome both the problem of resistance
and compliance. The number of parasites in the
early liver stage are low (hundreds, versus bil-
lions in the blood stage), reducing the proba-
bility that drug resistance–conferring mutations
might emerge. This feature could make these
liver-active compounds suitable for chemoprotec-
tion and, with sufficient demonstrated safety, for
mass drug-administration or malaria-elimination
campaigns.
To identify chemoprotective candidates, we
applied a liver-stage phenotypic screen to a
library of >500,000 small molecules. Our data
identify new scaffold families that exclusively
target liver stages that may provide prophylactic
protection, as well as new scaffolds that act
against known targets such as dihydroorotate
dehydrogenase (DHODH). These data comprise
new leads for antimalarial open-source drug
discovery.
Primary screening results
Previous high-throughput screens for antima-
larial compounds have generally focused on the
ABS, which can be readily cultured en masse
(6–8). To discover hits with possible protective
activity, blood stage–active compounds have been
further retested against malaria hepatic stages,
often using sporozoites from the rodent malaria
species Plasmodium yoelii or Plasmodium berghei
(9, 10). Because there are no suitable methods for
axenically culturing sporozoites (which are respon-
sible for liver-stage infection), this retesting has
required the production of infected laboratory-
reared mosquitoes and hand dissection of the
sporozoite-infected salivary glands from mos-
quito thoraxes. Despite this complex challenge,
thousands of compounds have been examined
by using this general workflow progression, lead-
ing to previously unidentified chemoprotective
candidates, including KAF156 (11), KDU691 (12),
DDD107498 (13), and BRD3444 (14). However,
this approach would not reveal compounds that
might protect from infection without affecting
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blood stages nor identify compounds that mod-
ulate human hepatocyte targets and prevent
parasite liver-stage development.
Recently, a screening method was developed
that was suitable for testing many compounds
against liver-stage parasites (10). This assay (Pbluc)
relies on an antifolate-resistant P. berghei rodent
parasite that constitutively expresses luciferase
during the sporozoite stage (15). Sporozoites are
dissected frommosquitoes, washed, and layered
on confluent HepG2 cells that have been pre-
incubated with compounds. If the parasites are
able to establish a successful exoerythrocytic stage
infection, even if only 1 to 2% of the hepatocytes
are infected, the cultures will emit enough light
in the presence of luciferin to be detected with
sensitive instruments. Light intensity is propor-
tional to parasite infection rate, and this simple
assay can be run by using 1536-well plates. The
P. berghei system has a distinct advantage over
the human pathogen, P. falciparum, in that this
parasite can infect a variety of hepatoma cell
lines, which results in ease of use and reprodu-
cibility. Furthermore, the development period
is only 48 hours, which means that hepatocyte
cultures do not overgrow, and special coculture
systems are not needed. Sporozoite yields are
generally higher, and there are fewer biosafety
precautions. In addition, because cellular detox-
ification systems have been generally lost from
hepatoma cell lines, compounds remain potent,
easing their discovery. The assay has shown to be
very predictive of causal prophylactic activity.We
thus sought to apply this screeningmethod to a
large library, with the goal of finding a larger
selection of starting points for chemoprophylactic
drugs.
Screening was conducted by using a library
of 538,273 compounds from Charles River con-
sisting of smallmoleculeswith an averageweight
of 369 Da (60.06 to 1298 Da). The library was
mostly drug-like (versus probe-like), with an aver-
age logP of 3, an average number of hydrogen
bond donors of 1.1, and 5.9 hydrogen bond ac-
ceptors. On average, each compound had 6.2
rotatable bonds; 5270 compounds were repre-
sented in duplicate or triplicate (table S1). Sub-
stantial structural redundancy was included in
the library to establish structure-activity relation-
ships in scaffold families. In contrast to many
previously published studies (6–8), all the com-
pounds in the library, including hits and neg-
atives, have structures and are commercially
available, facilitating use by the community.
The screen was run over an 18-month period,
with ~20,000 compounds screenedweekly (Fig. 1)
to accommodate the time-consuming production
of infected Anopheles mosquitoes. Each week,
a team dissected ~1000 mosquitoes, from which
the sporozoites were isolated and cleaned. Ap-
proximately 1000 sporozoites were added in a
5 ml volume per well plate by using a bottlevalve
instrument to a lawn of HepG2-CD81 cells that
had been prespotted into the 1536-well plates
with 50 nl of compounds at 0.5 to 7.84mM (Fig. 1).
After a 48-hour incubation, luciferin was added,
and luminescence was measured. Because a
compound that kills hepatocytes could result
in reduced luciferase signal (because parasites
presumably need a live hepatocyte for intra-
cellular survival), we also tested a randomly
selected subset of the compounds (~179,600) for
hepatocyte toxicity using a Cell-Titer Glo assay
(materials and methods) that measures the
number of viable cells based on the amount
of adenosine 5′-triphosphate (ATP) that is pres-
ent (HepG2tox).
Cheminformatic analysis of the
primary screen
After collating the data and ranking the per-
centage inhibition for 538,273 compounds from
the 1536-well screen, 64,172 compounds showed
inhibition of >50%, and 21,336 showed inhibition
levels of >75% (Fig. 1). Although a higher-than-
normal number of false positives and negatives
is expected for a single-point screen (data may
be affected by edge effects, transfer errors, or
variation in dispense volumes), the initial screen
was informative. For example, the library included
197 ABS-active compounds that had been previ-
ously tested in a high-content imaging screen of
P. yoelii liver stages (9), including 18 compounds
with activity of less than 10 mM (data file S1). Of
those, 15 showed >50% inhibition in the primary
screen. Likewise, themajority of compounds that
were considered inactive in the high-content
imaging screen showed <75% inhibition here
(129 out of 163) (data file S1).
To further evaluate the quality of the primary
Pbluc data, we performed compound clustering
(Fig. 2 and data file S2). We hierarchically clus-
tered all 538,273 compounds in the primary
screen and separated clusters using a minimum
Tanimoto coefficient of 0.85 similarity (materials
and methods). From this, we identified 281,090
compound clusters, with an average hit fraction
of 0.016 ± 0.112. We calculated the probability of
hit enrichment (>83% inhibition in Pbluc) by
chance for each cluster (data file S2). Not un-
expectedly, certain scaffold families with known
activity against Plasmodium liver stages, such as
the phosphatidylinositol-4-OH kinase (PI4K)–
inhibiting imidazopyrazine family (12), included
a high proportion of highly active compounds.
For example, with an imidazopyrazine group
(family 227215), 11 of the 14members were highly
active [average 81.1%, log10 probability of dis-
tribution by chance (log10 p) = –15.16] (Fig. 2A),
and these were similar to the known imidazo-
pyrazine KDU691 (12). Likewise, scaffold family
37533 consisted of four members where all four
members in the library were more than 80%
active (average 88.4%). All were very similar to
MMV390048, another PI4K inhibitor (Fig. 2B).
Atovaquone-like scaffolds (cluster 68966) were
also present in the library and active at rates
higher than expected by chance (eight of nine
members active, log10 p = –10.88) (Fig. 2C). The
hit fractions of cluster 69866, 37533, and 227215
(0.89, 0.75, and 0.79, respectively) are all in the top
1.1 percentile when considering the entire library.
Several additional scaffold families with known
activity against malaria parasites were also found
in the library and showed activity, although these
families would not have been discovered with
cluster analysis at the similarity thresholds used.
For example, cycloguanil (83.4% inhibition) was
found to be active in the 538,273-compound
library but had only one close relative (> 85%
Tanimoto similarity), which was not active
(log10 p = –1.31). Relaxing the stringency, how-
ever, revealed three other relatives, one of which
was also primary hit (log10 p = –2.42) (Fig. 2E).
Likewise, compounds similar to DSM265 (16)
and DDD107498 (Fig. 2, F and G) (13), two other
potent compounds with nanomolar activity
against exoerythrocytic stages, were also identified
through relaxed similarity searching but were in
clusters that might have arisen through chance
(MMV011256, one of three active, log10 p = –1.35;
MMV1478835, two of nine active, log10 p –1.40;
MMV1370261, one of two active, log10 p = –1.50) or
were singletons (MMV1386820).
Reconfirmation
To obtain a reasonable working set for reconfir-
mation (9989 compounds), we selected com-
pounds that showed >83% Pbluc inhibition
and HepG2tox of less than 50%, when available
(data file S3). Cut off and filtering criteria did not
bias physicochemical properties of primary hits,
whose subset compounds had similar properties
to the larger library, with weights of 388 Da
(985.1 to 136.2), 1.1 hydrogen bond donors, 5.5
hydrogen bond acceptors, and 5.9 rotatable bonds
on average (fig. S1 and table S2). To confirm
primary hits, the location of wells with possible
active compounds were identified, and then a
hit-picking instrument was used to reassemble
a collection for reconfirmation (data file S3).
We arrayed these hit compounds in eight-point
dose-response format (5 nM to 10 mM) and
reassessed their potency and efficacy in duplicate
in three different assays—including the Pbluc
assay, theHepG2tox assay, and a counterscreen—
to test whether a given compound would inhibit
firefly luciferase in a biochemical assay (Ffluc).
Altogether, complete Pbluc dose-response curves
could be fitted for 5942 compounds [half-
maximal inhibitory concentration (IC50) < 15.4 mM,
average 4.71 mM], and 681 showed complete Pbluc
inhibition at all tested concentrations (18 com-
pounds) or an IC50 of <1 mM (663 compounds)
(data file S3). However, of the 5942 reconfirmed
hits, 790 demonstrated moderate inhibition of
hepatocyte viability [HepG2tox CC50 (50% cyto-
toxicity concentration) < 2X Pbluc IC50 and
HepG2tox CC50 < maximum tested concentra-
tion], and 465 of these also interferedwith firefly
luciferase production (Ffluc IC50 < 2X Pbluc IC50
and Ffluc IC50 <maximum tested concentration)
(data file S3).
Adding these data to our cluster analysis
(Fig. 2) showed enrichment of false positives
arising from the use of luciferase as a surrogate
for parasite development. For example, 526 scaf-
folds of the imidazopyridine-carboxamide group
(128188) were found in the library of 538,273
compounds, of which 145 were in the hit list
(log10 p < –100) (data file S2). Of these, 116
Antonova-Koch et al., Science 362, eaat9446 (2018) 7 December 2018 2 of 8
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showed biochemical luciferase inhibition <10 mM
(29 less than 1 mM) (data files S2 and S3). Vis-
ualization showed that other less abundant
scaffolds, such as those in cluster 30984 or
4198, also showed enrichment of luciferase
activity at higher rates than expected by chance
(Fig. 2 and data file S2). Likewise, some enriched
scaffold families (log10 p = –14.45) were clearly
toxic to human cells (cluster 95979) (Fig. 2 and
data file S2).
To further establish the integrity of the hits,
we next assembled a collection of compounds
for third-round, independent testing. The non-
toxic second round hits were filtered through
the general medicinal chemistry compound
filters by using Biovia ScienceCloud. This fil-
tering removed 619 compounds that either failed
Lipinski’s rule of 5 (based on calculated proper-
ties) as a surrogate for “drug-like”; had structural
features consistent with high chemical reactivity
or instability; had a high likelihood of nonspecific
covalent interaction, such as thiourea; or was an
enone, which would react with nucleophiles such
as thiols or disrupt disulphide bonds (17). The
remaining set was then prioritized on the basis
of potency (IC50) and calculated lipophilicity
(cLogP), yielding 953 compounds prioritized
as follows: 445 actives with IC50 < 1 mM (most
potent—no additional cLogP filter), 268 actives
>1 mM but clogP < 2.5 (low lipophilicity com-
pounds with lower potency), and 240 actives
>1 mM but 2.5 < clogP < 3 (as above, with mod-
erate lipophilicity).
With this set of 953 compounds, we inter-
rogated the databases of commercially availa-
ble compounds for acquisition, confirmation,
and further profiling; 631 (repurchased valida-
tion set) were available and thus further char-
acterized (data file S4). These compounds were
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Fig. 1. Screen workflow. (A) The Charles River library (538,273
compounds) was plated into 1603 384-well plates. For the primary Pbluc
single-point screen, compounds from four of the 384-well plates were
transferred with a pin-tool instrument (50 nl per well) into 1536-well assay
plates containing seeded HepG2 cells (3 × 103 cells per well).The next day,
P. berghei luciferase–expressing sporozoites were freshly prepared from
infected Anopheles stephensi mosquitoes, and ~1000 sporozoites in a
5 ml volume were added to each well. After 48 hours, P. berghei–Luc
growth within hepatocytes was measured with bioluminescence. (B) To
prepare source plates for the first round of reconfirmation (second round
of screening), the 9989 hit compounds were transferred from the original
384-well library with an automated hit-picking system and serially
diluted into eight points (1:3 dilutions) for dose-response screening in
duplicate. The hit compounds (50 nl per well) in serial dilutions were
acoustically transferred into assay wells containing HepG2 cells for Pbluc
and HepG2tox assays. In addition, biochemical recombinant luciferase
inhibition assay (Ffluc) were also performed. (C) For final reconfirmation
(third round), 631 compounds prepared from re-sourced powders and
were serially diluted (10 points, 1:3 dilution) and plated into Aurora 1536-
well compound plates. Compounds (50 nl per well) were acoustically
transferred into 1536-well assay plates. Multiple dose-respose assays such
as Pbluc, HepG2tox, Ffluc, and ABS-Sybr were performed to determine
IC50 in the third round of screening. A P. vivax liver schizont formation
high-content assay in single-point (2X) was also performed.
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arrayed within the 1536-well plate format into
10-point dose response, tested in duplicate (tech-
nical replicates), and counterscreened in multiple
different assays, repeated up to four times with dif-
ferent sporozoite batches. Two separate HepG2tox
assays and one Ffluc also were performed. Retest-
ing showed a high reconfirmation rate (82% with
an average Pbluc IC50 < 10 mM) and 376 com-
pounds with Ffluc IC50 and HepG2tox CC50 < 2×
Pbluc IC50 (fig. S2). All compounds were also
tested in dose-response format against ABS of
the multidrug-resistant P. falciparum Dd2 strain,
using a standard SYBR green incorporation blood-
stage assay that identifies compounds that pre-
vent growth and development (ABS-Sybr; four
biological replicates) (6).
Activity against P. vivax
To better understand species specificity, the afore-
mentioned repurchased validation set (631),
reconfirmed in eight-point dose assays with
Pbluc, was also tested against the human path-
ogen P. vivax. For this, we used a single-point
high-content imaging screen (PvHCI), with pri-
mary humanhepatocytesmaintained in 384well
plates. Hepatocyteswere inoculatedwith P. vivax
sporozoites dissected frommosquitoes fed with
blood obtained from malaria patients. The fol-
lowing day, compounds were added to a final
concentration of 10 mM and then reapplied at
days 2 and 3 and 4. After compound treatment,
cultureswere fixed onday6 after infection, stained
with immunoreagents against PvUIS4 (materials
and methods), and we performed high-content
imaging andanalysis to score eachwell for growth
of liver schizonts. Of the 631 compounds screened
in this single-point assay, 163 were confirmed to
inhibit P. vivax schizont growth by at least 70%
(normalized to positive control KDU691) (data file
S4) in at least one of two biological replicates, and
91 were confirmed in both replicates (fig. S2). This
confirmation rate was achieved despite several
critical differences between the rodent and
human assays, including hepatic metabolism
of unoptimized compounds and addition of
compound on day 1 after infection (PvHCI)
instead of preinfection (Pbluc). Furthermore,
12 compounds (fig. S2) were considered not
reconfirmed in a third round of P. berghei testing
but were nevertheless still active in P. vivax
(for example, MMV1288041 inhibited P. vivax
by 100% in both replicates and had an IC50 of
P. berghei 3.27 mM in second-round testing),
highlighting how experimental design and anal-
ysis constraints (for example, curve-fitting com-
pounds that did not fully inhibit growth in Pbluc
at 10 mM, the highest concentration tested, would
be considered “not confirmed”) could lead to
possible false negatives. On the other hand, com-
pounds could lose potency over repeated use
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Fig. 2. Cluster analysis. (A) For display, 405 compounds from 68 clusters
that show a P value ≤ 0.05, cluster size ≥ 4, and hit fraction ≥ 0.75 are
presented (data file S2). Most common substructure (MCS) per cluster is
identified by using the top three active compounds, and a hierarchical tree
was constructed from the MCSs to illustrate the intergroup connection.
Compound members were then added to surround MCS nodes. All
compound nodes are colored by hit status and shaped by other
annotations. Primary hits are orange, reconfirmation hits (Pbluc IC50 < 10 mM)
are red, third-round reconfirmation set (631 compounds) is purple,
and others are light blue. P. falciparum asexual blood state–active
compounds (ABS-Sybr IC50 < 10mM) are indicated by squares, luciferase
inhibitors (Ffluc IC50 < Pbluc IC50 / 2) are indicated by triangles,
hepatocyte toxic (primary HepG2tox > 50% or HepG2tox CC50 < Pbluc
IC50 / 2) are indicated by diamonds, and the rest are shown as circles.
(B to G) Active compounds in selected clusters [(B), (C), and (D)] with hit
fractions of less than 0.75, as well as examples of singleton hits that are
similar to the known antimalarial compounds, (E) cycloguanil, (F)
DDD107498 (13), and (G) DSM265 (data file S3) (16).
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owing to freeze-thaw and hydration, there could
be differences in liver-stage schizogony between
P. vivax and P. berghei (liver schizonts produce
far greater quantities of liver merozoites over
six additional days of development in com-
parison to the 72-hour liver cycle of P. berghei),
and the wild-type P. vivax may be more drug-
sensitive than P. berghei–ANKA-GFP-Luc-SMCON
or P. falciparumDd2, both of which are resistant
to some antifolates.
Activity against P. falciparum
blood stages
To further study the function of the third-round
compounds, we next testedwhether the repurch-
ased validation set of 631 would be active against
P. falciparum ABS parasites. The active set
showed several known chemotypes. One example,
MMV1468363, showed a high degree of similarity
to tetracyclic benzothiazepines, which are known
cytochrome bc1 inhibitors (18). There were seven
closely related members of the tetracyclic benzo-
thiazepines scaffold family in the larger library,
and six of the seven showed inhibition rates of
greater than 85% in the primary screen (log10 p =
–7.969, cluster 157835) (Fig. 2). Another recog-
nizable scaffold was that of MMV1005663, sim-
ilar to the possible FabI inhibitor trichlocarban,
as well as the liver stage–active malaria box mem-
ber, MMV665852 (19). This latter compound is
associated with amplifications of the gene encod-
ing phospholipid flippase, pfatp2 (19). This com-
pound series (cluster 84381) was represented
multiple times in the library, with all five tested
members showing strong inhibition (average 93%,
log10 p = –7.34) in the primary screen (Fig. 2).
Three hundred ninety-eight liver-active com-
pounds were inactive in P. falciparum ABS-Sybr
(average IC50 of > 10 mM) (fig. S2), highlighting
the rich new untapped chemical space that was
sampled by using this screening cascade when
compared with the ABS-first cascade. Although
some could be due to species-specific activities,
130 compoundswere active against both P. vivax
(in at least one replicate) and P. berghei schizonts
(fig. S2) but were inactive against ABS. Although
our use of antifolate-resistant P. berghei and a
multidrug-resistant P. falciparum strain may in-
fluence this result, most of these scaffolds likely
affect parasite or human processes that exist only
in the hepatic stages. These scaffolds generally did
not show any similarities to known antimalarials,
but several of these were supported by strong
statistical overrepresentation in the primary screen
(Fig. 2 and data file S2). For example, seven of
the ninemembers of the imidazoquinoline cluster
(112845)were active in the primary screen (log10 p=
–8.89) (Fig. 2).
Mechanism of action studies reveal an
abundance of mitochondrial transport
chain inhibitors
To further investigate the mechanism of action
of 13 of the most potent ABS hits (Fig. 3A), we
acquired additional compound from commercial
vendors. Because most, if not all, target identifi-
cation methods require activity in P. falciparum
blood stages, all compounds selected for initial
target discoverywere active against ABS parasites,
with an average IC50 of 465 nM (range of 13 nM to
1.2 mM).
As an initial pass, we first subjected the com-
pounds to metabolic profiling (20). This liquid
chromatography–mass spectrometry (LC-MS)–
based method measures several hundred metab-
olites and identifies those that show statistically
significant increases or decreases upon parasite
compound exposure (data file S5).Whereas three
gave ambiguous results, 10 of the 13 analyzed
scaffolds gave a metabolic profile signature anal-
ogous to that of atovaquone (fig. S3), indicating
that these 10 most likely interfere with one or
more targets in themitochondrial electron trans-
port chain (mETC), a known druggable pathway
for P. falciparum blood and liver stages (Fig. 3A).
The set of 13 compounds represents 11 distinct
scaffolds (Fig. 3B), so this degree of functional
overlap would not have been predicted by struc-
ture alone. To our knowledge, none of the mo-
lecules have been previously identified as acting
against the mitochondrial electron transport
pathway.
To further confirm that these 10 compounds
(representing eight chemotypes) inhibited the
mETC, we took advantage of a transgenic parasite
line that overexpresses the Saccharomyces
cerevisisae dihydroorotate dehydrogenase (Dd2-
ScDHODH) (21). Unlike the type-2 P. falciparum
enzyme that is dependent on cytochrome bc1 for
ubiquinone, the cytosolic type-1 yeast enzyme can
use fumarate as an electron acceptor. This allows
the transgenic parasites to bypass the need for
ETC activity to provide ubiquinone to PfDHODH
(21). Compounds that target PfDHODH or other
enzymes along the mETC lose potency in the
Dd2-ScDHODH transgenic cell line. As expected,
the Dd2-ScDHODHparasites showmarked (24.8
to >1000-fold) resistance to the 10 compounds
with the mETC metabolic profile (Fig. 3C and
table S3). Furthermore, a variation of this func-
tional assay can distinguish between inhibitors
of PfDHODH and cytochrome bc1. Specifically,
the addition of proguanil to Dd2-ScDHODH pa-
rasites restores the inhibitory capabilities of cyto-
chrome bc1 inhibitors; however, growth is not
affected in the case of PfDHODH inhibitors. Three
out of six mitochondrial inhibitors tested in these
conditions were not inactivated by proguanil,
suggesting a profile consistent with PfDHODH
inhibition (Fig. 3C and table S4). To further in-
vestigate mitochondrial inhibition, and because
there are multiple potential targets, we used an
in vitro evolution and whole-genome analysis
(IViEWGA) approach (22) to further elucidate the
molecular target of several of the compounds,
including MMV1454442, MMV1432711, and
MMV142795. First, three independent lines
resistant to MMV1454442 were isolated after
growing in sublethal concentrations of com-
pound. The resistant clones showed an average
4.2-fold shift in the IC50 (range of 1.9 to 9.4) (table
S5). Whole-genome sequencing of the nine clones
(three each from three independent selections), as
well as the drug-sensitive parent clone to 78-fold
coverage (table S6), revealed that the resistant
lines carried either a single-nucleotide variant
Phe188Ile (Fig. 3D and data file S6) or a copy
number variant (table S8) in P. falciparum
dihydroorotate dehydrogenase (PF3D7_0603300),
which isawell-validateddrug target inP. falciparum
(16). This result is consistent with proguanil not
affecting growth inhibition in Dd2-ScDHODH
parasites (Fig. 3C).MMV1454442, an amino-triazol,
although somewhat similar to a pyrrole-based
DHODH inhibitor (23), is a previously uniden-
tified chemotype, which would not have been
predicted with structural information alone. The
Phe188 residue is located in the species-selective
inhibitor-binding pocket of PfDHODH (24) and
has been shown to be in contact with the known
DHODH inhibitor leflunomide (25) and the tri-
azolopyrimidine DSM338 (Fig. 3D) (26). Further-
more, mutation of this residue has been shown to
confer resistance to the alkylthiophene inhibitor
Genz-669178 (27), suggesting that MMV1454442
likely shares the same space (Fig. 3D).
IViEWGA of MMV1432711-resistant parasites
revealed they had acquired one of two non-
synonymous single-nucleotide variants (SNVs)
in the gene encoding cytochrome b (data file S7).
The amino acid mutations found, Tyr126Cys and
Val259Leu, are located within helix C in the
ubiquitinol-binding pocket of cytochrome b,
a catalytically important subunit of the cyto-
chrome bc1 complex that contains two reaction
sites, Q0 (ubiquitinone reduction site) and Qi
(ubiquitinol oxidation site). MMV1432711 has a
chemical scaffold similar to that of the Qi in-
hibitors, sowe used a homologymodel of PfCYTb
(Fig. 3E) to resolve themode of binding. Docking
into the model showed that MMV1432711 is likely
a class II inhibitor. The allele Y126C was prev-
iously reported to confer resistance to decoquinate
(28) and MMV008149 (29). To our knowledge,
allele Val259Leu has not been reported in the
literature.
For compound MMV1427995 {2-[(5,6-diphenyl-
1,2,4-triazin-3-yl)thio]-1-(pyrrolidin-1-yl)propan-1-
one}, in vitro evolution studies yielded two
resistant lines that were cloned for further phe-
notyping and whole-genome sequencing (tables
S5 and S6). Clones showed an average 2.6-fold
IC50 shift (range of 1.8- to 3.4-fold) in susceptibility
to MMV1427995 (table S5). Sequencing revealed
that both clones carried the amino acid mutation,
Arg95Lys, in cytochrome b, located in the matrix-
oriented region of the protein after the second
transmembrane domain (Fig. 3E and data file S6).
One clone also carried an additional Pro102Thr
mutation in cytochrome c oxidase subunit 1. This
mutation is located between the second and third
transmembrane domain, is not located in any
of the iron or copper redox centers, and is, to
our knowledge, the first described mutation in
cytochrome c oxidase selected for during com-
pound exposure. However, this mutation did not
induce a higher resistance level than did the
Arg95Lysmutation alone andmay thus represent
a compensatory mutation. MMV1427995 is a dif-
ferent scaffold family (also overrepresented
in the initial set of screening hits) from known
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Fig. 3. Target identi-
fication studies.
(A) Chemical
structures and IC50 of
select antimalarial
compounds identified
as hits. Tanimoto
clustering demon-
strates that most
molecules are struc-
turally distinct,
although some share
similar scaffolds.
(B) Metabolomic
analysis reveals
that 10 of the 13
compounds likely
target the mETC and
pyrimidine bio-
synthesis pathways.
Robust increases in
pyrimidine bio-
synthesis precursors
N-carbamoyl-L-
aspartate (CA) and
dihydroorotate (DHO)
are signatures of
metabolic disruption
of de novo pyrimidine
biosynthesis. The
metaprints for
MMV1068987 and
MMV1431916 are sim-
ilar to the metaprint
of the PfATP4 inhibi-
tor KAE609, whereas
the metaprint for
MMV011772 is
inconclusive. The
numbers below each
compound name
indicate the Pearson
correlation with an
atovaquone profile
(fig. S3). (C) IC50 of
each compound in
Dd2 cells expressing
S. cerevisiae DHODH
normalized to parent.
The transgenic
Dd2-ScDHODH strain
expresses the cyto-
solic type 1 DHODH
from S. cerevisiae
(ScDHODH) and is
resistant toP. falciparum
mETC inhibitors. Abla-
tion of compound
activity in this cell line
relative to its parent
indicates inhibition of
DHODH or downstream effectors in the mETC such as Cytbc1. Atovaquone, a known Cytb inhibitor, was included as a positive control, whereas other
licensed antimalarials with mETC-independent mechanisms of action serve as negative controls. (D) Location of Phe188Ile mutation found in whole-genome
sequences ofMMV1454442-resistant parasites by using a crystal structure of PfDHODH (4ORM) (27). Amino acid residue 188 is highlighted inmagenta.The
structure shows a known PfDHODH inhibitor, DSM338 (27), cocrystalized with the protein. (E) Homology model of PfCytb (from PDB 1BE3) (35) with
Tyr126Cys and Val259Leumutations (highlighted in magenta) fromMMV1432711-resistant parasites.The Arg95 has previously been implicated in atovaquone
binding and resistance (36).
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P. falciparum cytochrome bc1 inhibitors, and its
target would not have been predicted through
similarity searching.
Given the high number of mitochondrial in-
hibitors in the dataset, we further examined the
set of 631 compounds (repurchased validation
set). All 631 compounds were tested in du-
plicate in eight-point ABS dose response in two
P. falciparum D10–derived lines (21), one of
which expresses ScDHODH (fig. S4 and data
file S7) in the presence and absence of 1 mM
proguanil in duplicate (~80,000 data points).
Of the 136 compounds with ABS activity, visual
inspection showed that 78 were likely not mito-
chondrial inhibitors, and 58 showed profiles
consistent with mitochondrial inhibition (figs.
S4 and S5 and data file S7). Of these, 10 were
clear DHODH inhibitors (including the three
shown in Fig. 3), one was a potential DHODH
inhibitor, and 47 were likely or possible cyto-
chrome bc1 inhibitors (including all nine from
Fig. 3 that were tested). Strong nonrandom
structure-activity relationships are evident (fig.
S5), validating the assay. For example, six of the
seven compounds that were more than 55%
similar to MMV1042937 (fig. S5, fourth row) in
the set of 631 were predicted to be cytochrome
bc1 inhibitors (log10 p = –6.09). The seventh,
MMV1457596, was missed because the IC50 were
all >10 mM, but visual inspection of the curves
showed an ~75% reduction in signal at 10 mM for
the ScDHODH line relative to the PfDHODH line
(data file S7).
Discussion
Previous open-access high-throughput screens
have had a great impact on malaria research,
and we anticipate that our data provide a rich
resource in the search for new antimalarials.
Despite the reliance on a nonhuman malaria
species for screening, the repeated rediscovery
of chemotypes with known, potent activity against
P. falciparum blood stages and P. vivax liver
schizonts, or clinical efficacy in humans, shows
that the data from this rodent malaria model are
predictive. Furthermore, liver schizonticidal ac-
tivity is a required component of next-generation
antimalarials proposed byMedicines for Malaria
Venture, critical components of which include
prophylactic and chemoprotective liver-stage
efficacy after single exposure (TCP4) (30). Another
advantage of the Pbluc assay is the reduced me-
tabolic capacity of the host cells used; this should
result in a higher hit rate withmetabolically liable
compounds in a high-throughput phenotypic
screen. Last, although it is possible that some
compounds were missed through the use of a
rodent parasite, rodent malaria remains an ef-
ficient and important in vivo model for drug
efficacy testing; compounds that do not act in
this model would be costlier to progress into
animal causal prophylaxis testing. In addition,
some of the compounds that have activity here
may eventually show activity against P. vivax
hypnozoites, and if a radical cure chemotype is
to be found, its discovery would be made much
more likely through elimination of liver schizont-
inactive compounds. The use of the low-cost
rodent model allowed a much higher number of
compounds to be evaluated than would be pos-
sible with human parasites, which can be dif-
ficult and expensive to acquire. The large size
of the library used here facilitated compound
clustering and allowed a probabilistic identifi-
cation of active families.
The high number of parasite mitochondrial
inhibitors (57) that were discovered with com-
bined target identification methods is perhaps
not surprising given that compounds were se-
lected for target identification on the basis of
potency, and substantial work has shown that
mitochondrial inhibitors are very potent anti-
malarials. Nevertheless, the dataset contains a
rich set of other ABS scaffolds that could still
be good starting points for medicinal chemistry
efforts designed to improve potency, selectivity,
and reduced toxicity. The picomolar inhibitor
and clinical candidate KAE609 was derived from
an ~90 nM IC50 starting point that was dis-
covered in a high-throughput ABS screen (31).
Although our target identification efforts
showed that several compounds with activity
across species were mostly in known target
classes, a much larger number of compounds
were active in the liver stages and had no ac-
tivity in the blood stages. These presumably
act against host pathways that the parasite
requires for development, or alternatively, the
infected cell may be weakened by the presence
of a parasite and be more susceptible to killing
by compounds that target essential host cellular
processes. It is worthwhile to mention that be-
cause there are no reported antimalarial com-
pounds with exclusive prophylactic activity, and
methods for target identification are not readily
available for compounds that do not act in the
blood stage, we are unable to conclude much
about their mechanism of action. Nevertheless,
the scaffolds should still represent important
starting points for prophylaxis stage drugs and
exploring new mechanism of actions.
In theory, liver-stage antimalarial compounds
could function as more cost-effective “chemical
vaccines” that could replace conventional vac-
cines in malaria-elimination campaigns, provided
sufficient safety. A fully protective conventional
vaccine has never been developed for malaria
(32); vaccines are very species-specific (and po-
tentially strain-specific), whereas chemotherapy
is generally not, and vaccines, which typically
consist of recombinant protein or a heat-killed
organism, require maintenance of a cold chain.
In the case of the irradiated or attenuated cryo-
preserved sporozoite vaccine (33), the cost of
goods (sporozoites that are hand-dissected from
infected mosquitoes) will be much higher than a
small-molecule therapy.We estimate that it costs
10 cents per well to create the 1000 sporozoites
needed for one well of a 1536-well plate. Creating
enough sporozoites to immunize a humanwould
cost many times this amount.
In an analogous situation, long-acting, inject-
able HIV drugs have now been developed, and
their deploymentmay help to prevent the spread
of the HIV virus (34). Such intramuscular or sub-
cutaneous chemoprotection injections or “chem-
ical vaccines” can be deployed in resource-poor
settings, and patient compliance is not as much
of an issue as with standard, orally available
tablet drugs. Because the injectable typically
consists of a small molecule, refrigeration and
maintenance of a cold chain may not be needed.
The cost of goods for an injectable that needs to
be supplied once every 1 to 3 months will most
likely be lower than the cumulative cost of a
tablet that needs to be taken every day, even con-
sidering the cost of a syringe and a health care
worker to provide delivery. There are also other
low-cost deliverymethods, such as patches. Thus,
it seems entirely feasible that a contribution to
the eradication of malaria could come through
the use of a long-acting chemical vaccine.
Materials and methods
A detailed description is provided in the supple-
mentary materials.
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development.modes of action but solely targeting the parasites' liver stages, emerged as promising drug leads for further 
 mitochondrial electron transport were identified. Excitingly, several new scaffolds, with as-yet-unknownPlasmodium
Three rounds of increasingly stringent screening were used. From this regime, several chemotypes that inhibit 
Plasmodium berghei.and Goldberg). To do so, they devised a luciferase-reporter drug screen for the rodent parasite 
 investigated the possibilities of drugs against liver-stage parasites (see the Perspective by Phillipset al.Antonova-Koch 
 parasite. As an alternative strategy,Plasmodiumfrontline combination therapies, which target the blood stages of the 
Malaria parasites are evolutionarily prepared to resist drug attack. Resistance is emerging to even the latest
A path to tackle liver-stage parasites
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